Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416688 · ClinicalTrials.gov registry record
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
A clinical trial of Lung Cancer and Colorectal Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 146
- Enrollment target
- 20
- Study locations
NCT01416688: Completed study of Lung Cancer and Colorectal Cancer, sponsored by SWOG Cancer Research Network.
NCT01416688 is a study of Lung Cancer and Colorectal Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 146 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01416688, a study of Lung Cancer and Colorectal Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride. PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- PROCEDURE psychosocial assessment and care
- PROCEDURE assessment of therapy complications
Study Locations (20)
California
- East Bay Radiation Oncology Center - Castro Valley
- City of Hope Comprehensive Cancer Center - Duarte
- Epic Care-Dublin - Dublin
- Bay Area Breast Surgeons Inc - Emeryville
- Epic Care Partners in Cancer Care - Emeryville
- UC San Diego Moores Cancer Center - La Jolla
- Loma Linda University Medical Center - Loma Linda
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Contra Costa Regional Medical Center - Martinez
- El Camino Hospital - Mountain View
- Highland General Hospital - Oakland
- Alta Bates Summit Medical Center - Summit Campus - Oakland
- Bay Area Tumor Institute - Oakland
- Hematology and Oncology Associates-Oakland - Oakland
- Doctors Medical Center- JC Robinson Regional Cancer Center - San Pablo
Arizona
- University of Arizona Cancer Center-North Campus - Tucson
- The University of Arizona Medical Center-University Campus - Tucson
Illinois
- Saint Joseph Medical Center - Bloomington
- Illinois CancerCare-Bloomington - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2011-11-15 |
| Est. Completion | 2019-04-08 |
What the finished NCT01416688 record still lists
NCT01416688 is an observational study that tracks outcomes without assigning an intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT01416688 names 20 study sites across 3 states, led by California, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT01416688 about?
NCT01416688 is a clinical study titled "S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride". RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride. PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in ...
What is the current status of trial NCT01416688?
This trial is currently completed. The enrollment target is 146 participants. The study started on 2011-11-15. Estimated completion is 2019-04-08.
What conditions does trial NCT01416688 study?
This clinical trial studies the following conditions: Lung Cancer, Colorectal Cancer, Dermatologic Complications, Therapy-related Toxicity.
What interventions are being tested in trial NCT01416688?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), psychosocial assessment and care (PROCEDURE), assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT01416688?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01416688 being conducted?
This trial has 20 study locations across Arizona, California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01416688's enrollment target sits among peer trials
146 151st of 409 higher than 258 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI